Update shared on08 Aug 2025
Fair value Increased 15%The upward revision in Silence Therapeutics’ price target reflects significantly improved consensus revenue growth forecasts and a lower future P/E multiple, resulting in an increased fair value estimate from $32.37 to $37.26.
What's in the News
- Silence Therapeutics approved the application of Article 159 of its articles of association, effective from the recent AGM to the next annual general meeting.
- The company presented updated Phase 1 SANRECO study data for divesiran in polycythemia vera (PV), showing elimination of therapeutic phlebotomies and maintenance of hematocrit below 45% across all cohorts, with improved iron levels and no current competing therapies targeting red blood cells and hematocrit.
Valuation Changes
Summary of Valuation Changes for Silence Therapeutics
- The Consensus Analyst Price Target has significantly risen from $32.37 to $37.26.
- The Consensus Revenue Growth forecasts for Silence Therapeutics has significantly risen from 16.4% per annum to 30.5% per annum.
- The Future P/E for Silence Therapeutics has significantly fallen from 318.69x to 201.28x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.